Drugs / iNTS-GMMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06213506 | Jan 2024 → Aug 2026 | salmonellosis | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05480800 Comparator | Sep 2022 → Sep 2024 | salmonellosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iNTS-GMMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05480800 ↗ |
| Modality | Vaccine | “iNTS-GMMA low dose vaccine” NCT05480800 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT06213506 ↗ |